These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36814469)

  • 1. Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients' Needs?
    Jongbloed EM; Blommestein HM; van Schoubroeck HM; Martens JWM; Wilting SM; Uyl-de Groot CA; Jager A
    Breast Cancer (Dove Med Press); 2023; 15():147-161. PubMed ID: 36814469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
    Davie A; Traoré S; Giovannitti M; Pompilio G; Lambton M; Cakar E; Chatterjee A
    Glob Reg Health Technol Assess; 2023; 10():62-69. PubMed ID: 37811343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.
    Chang SH; Svensson M; Hsin-Min Wang G; Wang Y; Kang HR; Park H
    J Manag Care Spec Pharm; 2024 Sep; 30(9):942-953. PubMed ID: 39213142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
    Sra MS; Sasi A; Batra A; Bakhshi S; Ganguly S
    JCO Glob Oncol; 2024 Jul; 10():e2300433. PubMed ID: 39024528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China.
    Wei Q; Xu Y; Liu W; Guan X
    Cost Eff Resour Alloc; 2023 Nov; 21(1):91. PubMed ID: 38012661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
    Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
    Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    Royce M; Osgood C; Mulkey F; Bloomquist E; Pierce WF; Roy A; Kalavar S; Ghosh S; Philip R; Rizvi F; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    J Clin Oncol; 2022 Apr; 40(11):1155-1162. PubMed ID: 35084948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
    Raheem F; Ofori H; Simpson L; Shah V
    Ann Pharmacother; 2022 Feb; ():10600280211073322. PubMed ID: 35135362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
    Xie Q; Zheng H; Li Q
    Breast Care (Basel); 2022 Jun; 17(3):237-243. PubMed ID: 35957949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.
    Kramer A; Greuter MJE; Schraa SJ; Vink GR; Phallen J; Velculescu VE; Meijer GA; van den Broek D; Koopman M; Roodhart JML; Fijneman RJA; Retèl VP; Coupé VMH
    Ther Adv Med Oncol; 2024; 16():17588359241266164. PubMed ID: 39175989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system.
    Fenix-Caballero S; Sanchez-Vegas A; Alegre Del-Rey EJ; Epstein D; Garcia-Mochon L; Olry de Labry Lima A
    Eur J Health Econ; 2024 Apr; ():. PubMed ID: 38647974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
    Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
    J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation.
    Elazzazy S; Al-Ziftawi NH; Mohamed Ibrahim MI; Bujassoum S; Hamad A
    Front Oncol; 2024; 14():1413676. PubMed ID: 39114308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Zhang B; Long EF
    Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.
    Wang Y; Rui M; Guan X; Cao Y; Chen P
    Front Med (Lausanne); 2021; 8():658747. PubMed ID: 34150798
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.
    Takahashi N; Shimizu C; Shimomura A; Toi M
    Transl Breast Cancer Res; 2022; 3():3. PubMed ID: 38751527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.